top of page
PARTNERS WITH
Cetuximab
Anti-angiogenesis
MECHANISM OF ACTION
NAB against EGFR, decreasing cell growth, leading to apoptosis. Reduce TRPM6 expression
MECHANISM OF KIDNEY INJURY
Unclear
CLINICAL KIDNEY SYNDROME
Unclear
Extra-renal, GI, dermatological, and ILD
CARDIOVASCULAR ADVERSE EFFECTS
n/a
LYTE ABNORMALITIES
Hypomagnesemia, decreases apical TRPM6 expression in DCT, leading to Mag wasting
RISK FACTORS
MITIGATION STRATEGIES
Consider SGLT2i, possible increases expression of TRPM6
SUGGESTIONS
NOTES/COMMENTS
eGFR < 60 ml/min, no dose adjustment
PHARMACOKINETICS
Molecular Weight
152
Volume of Distribution
2-3L
Plasma Protein Binding
Metabolism
Bioavailability
Half-life elimination
112 hours
Time to peak
Excretion
Dialyzable?
REF:
PATHOLOGY SLIDES:
ENTRY UPDATES:
Raad Chowdhury
United States
Sep 25, 2022
bottom of page